1. A method of treating a patient suffering from fatty degeneration of the liver, comprising administering a therapeutically effective amount of a cysteamine product. ! 2. The method according to claim 1, wherein the fatty liver is selected from the group consisting of non-alcoholic fatty liver (NAFLD), non-alcoholic steatohepatitis (NASH), fatty liver, resulting from hepatitis, fatty liver, resulting from obesity, fatty degeneration of the liver resulting from diabetes, fatty degeneration of the liver resulting from insulin resistance, fatty degeneration of the liver resulting from hypertriglyceridemia, abetalipoprotein ii, glycogenosis, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy, and lipodystrophy. ! 3. A method of treating a patient suffering from a non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) disease comprising administering a therapeutically effective amount of a composition containing cysteamine or cystamine, or a pharmaceutically acceptable salt thereof. ! 4. The method according to claim 1, in which the total daily dose of the cysteamine product is approximately 0.5-2.0 g / m2. ! 5. The method according to claim 1, in which the total daily dose of a cysteamine product is approximately 0.5-1.0 g / m2. ! 6. The method according to claim 1, in which the composition is administered at a frequency of 4 or less times a day. ! 7. The method according to claim 6, in which the composition is administered twice a day. ! 8. The method according to claim 1, in which the composition is a dosage form with a delayed or controlled release, which provides increased1. Способ лечения пациента, страдающего жировым перерождением печени, включающий введение терапевтически эффективного количества цистеаминового продукта. ! 2. Способ по п.1, в котором жировое перерождение печени выбрано из группы, состоящей из неалкогольного жирового перерождения печени (NAFLD), неалкогольного стеатогепатита (NASH), жирового перерож
